• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

Men rowing on a river
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 26th October 2016

OHE at ISPOR Europe 2016: Risk-sharing, Differential Pricing, the Cancer Drugs Fund, and Patient Reported Outcomes

ISPOR’s 19th Annual European Congress is scheduled for 29 October – 2 November 2016 in Vienna. This post contains a summary of the contributions by various members of the OHE team. ISPOR’s 19th Annual European Congress is scheduled for 29 October…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

ISPOR’s 19th Annual European Congress is scheduled for 29 October – 2 November 2016 in Vienna. This post contains a summary of the contributions by various members of the OHE team.

ISPOR’s 19th Annual European Congress is scheduled for 29 October – 2 November 2016 in Vienna. This post contains a summary of the contributions by members of the OHE team. Individual contact details can be found through the links below or via our Meet the Team webpage if you would like any further information.

Short course: Risk-Sharing / Performance-Based Arrangements for Drugs and Other Medical Products. Sunday, 8:00-12:00, Hall F1 (L0), pre-registration is required.

Course tutors: Lou Garrison (University of Washington and OHE), Adrian Towse (OHE), Paolo Daniele Siviero (Principia III).

There is significant and growing interest among both the payers and producers of medical products for arrangements that involve a “pay-for-performance” or “risk-sharing” element. Issues surrounding theory and practice, including incentives and barriers, will be analysed along with several examples of performance-based schemes from Europe, the United States, and Australia. A hypothetical case study will be used in an interactive session to illustrate a systematic approach to weighing their applicability and feasibility.

Short course: Using Multi-Criteria Decision Analysis in Health Care Decision Making: Approaches & Applications. Sunday, 13:00-17:00, Hall F2 (L0), pre-registration is required.

Course tutors: Maarten IJzerman (University of Twente), Nancy Devlin (OHE), Martina Garau (OHE).

This course reviews the current multi-criteria decision analysis (MCDA) landscape, including a review of MCDA studies in health care and the different approaches employed. Best practices for conducting MCDA will also be outlined, as well as issues related to selecting the right data approach. Steps involved in conducting MCDA (such as criteria definition, scoring performance, weighting criteria, and uncertainty analysis), and current and future applications in health care decision making will be discussed. The presenters will draw from a number of real world examples and will reference the ISPOR Good Practice Guidelines for MCDA.

Plenary session: Differential Pricing of Medicines in Europe: Implications for Access, Innovation, and Affordability. Tuesday, 10:15-12:00, Hall A (L2).

Moderator: Lou Garrison (University of Washington and OHE).

Speakers: Adrian Towse (OHE), Sabine Vogler (Austrian Public Health Institute), Jo De Cock (National Institute of Health and Disability Insurance), Elias Mossialos (LSE).

This plenary session will explore options for a defined and systematic approach to promoting efficient differential pricing in Europe. Operational and political feasibility are key considerations in moving toward a sustainable policy.

Poster: A New Approach to Presenting Health States in Stated Preference Valuation Studies. Monday, displayed 8:45-14:15, author discussion hour: 13:15–14:15, D37.

Authors: Amanda Cole (OHE), Koonal Shah (OHE), Brendan Mulhern (University of Technology Sydney), Yan Feng (OHE), Nancy Devlin (OHE).

This study tests the impact of changing the presentation of health states in valuation studies, using the EQ-5D-5L. We conducted a two-arm discrete choice experiment (DCE) comparing the standard presentation of health states versus presenting them ‘in context’ of the entire descriptive system, finding that the ‘in context’ display led to fewer logical inconsistencies in responses and greater differentiation between the valuations of different levels of a health problem.

Presentation: Modelling the Impact of Reform to the Cancer Drugs Fund. Tuesday, 15:15-15:30, Hall F2 (L0).

Authors: Sarah Britton (Karlsberg Schaffer) (OHE), Martina Garau (OHE), Phill O’Neill (OHE) and Simona Bianchi (ABPI).

The Cancer Drugs Fund (CDF) was created in 2010 to pay for oncology indications that were not approved by the National Institute for Health and Care Excellence (NICE) and were not routinely available within the NHS in England. After a consultation process, it was agreed that from July 2016, NICE will appraise all new  licenced cancer indications and decide whether they are eligible for inclusion in the CDF, which will become a ‘managed access fund’. This research estimates the number of current CDF indications that may be eligible for the new CDF following its reform.

Issues panel: Is Balancing Value Demonstration for Payer and Patient Interests a Feasible Notion? Wednesday, 8:45-9:45, Hall E1 (L0).

Moderator: Kathleen Hughes (Avalere Health LLC).

Panellists: Adrian Towse (OHE), Sachin Kamal-Bahl (Pfizer), Alastair Kent (Genetic Alliance UK).

Maintaining patient focus in healthcare decision-making is a universally-accepted approach to ensuring positive outcomes. During this session panellists will debate how addressing payer and patient interests simultaneously could impact research functions, including broader evidence generation, patient-reported outcomes development, and establishment of quality measures encompassing payer/patient perspectives.

Issues panel: Can We Really Compare and Aggregate Patient-Reported Outcome Data Between People and Settings? Implications for Clinical Trials and Health Technology Assessment. Wednesday, 10:00-11:00, Hall A (L2).

Moderator: Nancy Devlin (OHE).

Panellists: Mike Herdman (OHE), Paula Lorgelly (OHE), Andrea Manca (University of York).

Patient-reported outcomes (PROs) are routinely collected in clinical trials, cohort studies and population health surveys. They are used to compare health across heterogeneous populations, e.g. across countries, different cultural settings and socio-demographic groups. This panel looks at whether PRO data are truly comparable across different groups of individuals and the implications of ignoring heterogeneity.

  • EQ-5D and PROMs
  • Events

Related News

MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!